Wondering if Regeneron Pharmaceuticals is a hidden gem or just fairly priced? You are not alone; investors everywhere are ...
Return on Assets (ROA): Regeneron Pharmaceuticals's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 3.67%, the company showcases ...
StockStory.org on MSN
Regeneron Earnings: What To Look For From REGN
Biotech company Regeneron (NASDAQ:REGN) will be announcing earnings results this Tuesday before market open. Here’s what you ...
StockStory.org on MSN
Why Are Regeneron (REGN) Shares Soaring Today
What Happened? Shares of biotech company Regeneron (NASDAQ:REGN) jumped 8.7% in the morning session after it reported ...
13d
A Look at Regeneron Pharmaceuticals’s Valuation Following Key European Regulatory Win for Libtayo
Regeneron Pharmaceuticals (REGN) just moved a step closer to expanding its cancer therapy portfolio in Europe after the European Medicines Agency’s committee issued a positive opinion for Libtayo as ...
REGN stock is presently trading nearly 38% lower than its 1-year peak, and is also being traded at a P/S multiple that is ...
Zacks.com on MSN
REGN Stock Up on Q3 Earnings Beat, Eylea HD Sales Increase
Regeneron Pharmaceuticals, Inc. REGN reported third-quarter 2025 adjusted earnings per share (EPS) of $11.83, which ...
Here’s why we believe Regeneron Pharmaceuticals (REGN) stock merits attention as a value addition. Currently, it is trading almost 44% lower than its 1-year peak and is also priced at a PS multiple ...
Regeneron Pharmaceuticals (REGN) is forecasting annual earnings growth of 7.41%, with revenue also projected to rise by 7% ...
Regeneron investors should embrace the fact that Eylea is no longer a growth product and focus on the rest of the commercial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback